Malignant meningitis

disorder

SNOMED 230156002CUI C0220654

Overview

By MedlinePlus, National Library of Medicine

NIH: National Cancer Institute Courtesy of the National Library of Medicine. Source: MedlinePlus.gov, National Library of Medicine. Not a substitute for medical advice.

Clinical Trials

Total Trials

Recruiting

With Results

Recent Trials

Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal Metastases

NCT07092202Phase 4Recruiting40 enrolled

Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis

NCT06230055Phase 4Recruiting37 enrolled

Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer

NCT06058988Phase 2Recruiting30 enrolled

Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma

NCT04661384Phase 1Active Not Recruiting10 enrolled

View all 4 trials on ClinicalTrials.gov

Related Conditions

Non-infective meningitis(parent)

Metastatic malignant neoplasm of meninges(parent)

Quick Facts

SNOMED CT: 230156002
UMLS CUI: C0220654
Fully Specified Name: Malignant meningitis (disorder)
Specialists: 0
Diagnostic Biomarkers: 0
Clinical Trials: 4

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Clinical content is derived from the SNOMED CT clinical ontology and curated medical knowledge graphs.